Supported by an independent research grant from Novartis Pharma SAS (Rueil Malmaison, France). The funding organization had no role in the design or conduct of this research.
Preliminary results of this study were presented as a poster at the Association for Research in Vision and Ophthalmology annual meeting, May 4–8, 2014, Orlando, Florida, United States.
Disclosure: S. Bonnin, None; R. Tadayoni, Alcon (C, S), Alimera Sciences, Inc. (S), Allergan, Inc. (S), Bausch & Lomb (C, S), Bayer Schering Pharma (S), DORC (C), FCI-Zeiss (C, S), Novartis Pharmaceuticals Corporation (C, S), Pfizer (S), Takeda (C), Thrombogenics (C, S); A. Erginay, Allergan, Inc. (C), Novartis Pharmaceuticals Corporation (C); P. Massin, Allergan, Inc. (C, S), Novartis Pharmaceuticals Corporation (C, S); B. Dupas, Allergan, Inc. (C), Novartis Pharmaceuticals Corporation (C)